echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A batch of drugs were investigated: Fengre Ganmao Granules, Ganmaoling Granules​...

    A batch of drugs were investigated: Fengre Ganmao Granules, Ganmaoling Granules​...

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical News, April 2 
     
    Shanghai: Discontinued sales of 7 drugs
     
    On March 31, Shanghai Municipal Drug Administration issued the 2021 Phase 1 Drug Quality Sampling Inspection Notice (hereinafter referred to as the "Notice").
     
     
    The notice stated that in order to strengthen drug quality supervision and management, standardize market order, and ensure the quality and safety of listed drugs and drug packaging materials , the Shanghai Drug Administration organized relevant units to conduct random drug quality inspections on drug production, operation and use units in this city.
     
    According to the notice, there are 7 drugs that do not meet the requirements, namely, cefuroxime sodium for injection, Adenophora radiata, Epimedium, vitamin B1 tablets, Imperata cylindrica, Magnolia officinalis, and magnesium stearate.
     
    The notice pointed out that for products that do not meet the requirements, the drug regulatory authorities at all levels have required relevant companies to take risk control measures such as suspension of sales and deactivation, and investigate and deal with them according to law.
     
     
    Jiangxi: Several commonly used drugs were investigated and punished
     
    Coincidentally, just a few days ago, the Jiangxi Provincial Food and Drug Administration issued the 2021 Phase 2 Drug Supervision Sampling Information Announcement (hereinafter referred to as the "Announcement").
     
     
    According to the announcement, in order to strengthen drug quality supervision and ensure the safety of drug use by the public, in accordance with the "Drug Administration Law" and related laws pharmnet.
    com.
    cn/" target="_blank">and regulations, and the Jiangxi Province drug sampling plan, the drug regulatory agencies and inspection agencies at all levels in the province are responsible for the production, operation and use of drugs in the province.
    The unit implemented supervision and random inspection.
     
      After verification, there are 9 batches of 8 varieties that do not meet the requirements, and the items that do not meet the requirements include traits, inspection, content determination, etc.
    After combing, it was found that only 2 of the 8 medicines were Chinese herbal medicine pieces, and the rest were all preparations, involving Fengreganmao granules, Ganmaoling granules, Tongbianling capsules, diclofenac sodium enteric-coated tablets and many other commonly used medicines.
     
      Announcements, Jiangxi Food and Drug Administration has instructed the relevant departments of the test do not meet the prescribed drugs include seizure, detention, suspension of sales, recall and other necessary control measures in accordance with relevant laws and regulations of the production companies and the sampling units in the investigation.
     
    Medical News, April 2 
     
      Shanghai: Discontinued sales of 7 drugs
     
      On March 31, Shanghai Municipal Drug Administration issued the 2021 Phase 1 Drug Quality Sampling Inspection Notice (hereinafter referred to as the "Notice").
     
     
      The notice stated that in order to strengthen drug quality supervision and management, standardize market order, and ensure the quality and safety of listed drugs and drug packaging materials , the Shanghai Drug Administration organized relevant units to conduct random drug quality inspections on drug production, operation and use units in this city.
     
      According to the notice, there are 7 drugs that do not meet the requirements, namely, cefuroxime sodium for injection, Adenophora radiata, Epimedium, vitamin B1 tablets, Imperata cylindrica, Magnolia officinalis, and magnesium stearate.
     
      The notice pointed out that for products that do not meet the requirements, the drug regulatory authorities at all levels have required relevant companies to take risk control measures such as suspension of sales and deactivation, and investigate and deal with them according to law.
     
     
      Jiangxi: Several commonly used drugs were investigated and punished
     
      Coincidentally, just a few days ago, the Jiangxi Provincial Food and Drug Administration issued the 2021 Phase 2 Drug Supervision Sampling Information Announcement (hereinafter referred to as the "Announcement").
     
     
      According to the announcement, in order to strengthen drug quality supervision and ensure the safety of drug use by the public, in accordance with the "Drug Administration Law" and related laws pharmnet.
    com.
    cn/" target="_blank">and regulations, and the Jiangxi Province drug sampling plan, the drug regulatory agencies and inspection agencies at all levels in the province are responsible for the production, operation and use of drugs in the province.
    The unit implemented supervision and random inspection.
     
      After verification, there are 9 batches of 8 varieties that do not meet the requirements, and the items that do not meet the requirements include traits, inspection, content determination, etc.
    After combing, it was found that only 2 of the 8 medicines were Chinese herbal medicine pieces, and the rest were all preparations, involving Fengreganmao granules, Ganmaoling granules, Tongbianling capsules, diclofenac sodium enteric-coated tablets and many other commonly used medicines.
     
      Announcements, Jiangxi Food and Drug Administration has instructed the relevant departments of the test do not meet the prescribed drugs include seizure, detention, suspension of sales, recall and other necessary control measures in accordance with relevant laws and regulations of the production companies and the sampling units in the investigation.
     
    Medical News, April 2 
     
      Shanghai: Discontinued sales of 7 drugs
      Shanghai: Discontinued sales of 7 drugs
     
      On March 31, Shanghai Municipal Drug Administration issued the 2021 Phase 1 Drug Quality Sampling Inspection Notice (hereinafter referred to as the "Notice").
     
     
      The notice stated that in order to strengthen drug quality supervision and management, standardize market order, and ensure the quality and safety of listed drugs and drug packaging materials , the Shanghai Drug Administration organized relevant units to conduct random drug quality inspections on drug production, operation and use units in this city.
    Medical Packaging Product Quality Medical Packaging Medical Packaging product quality and product quality
     
      According to the notice, there are 7 drugs that do not meet the requirements, namely, cefuroxime sodium for injection, Adenophora radiata, Epimedium, vitamin B1 tablets, Imperata cylindrica, Magnolia officinalis, and magnesium stearate.
     
      The notice pointed out that for products that do not meet the requirements, the drug regulatory authorities at all levels have required relevant companies to take risk control measures such as suspension of sales and deactivation, and investigate and deal with them according to law.
     
     
      Jiangxi: Several commonly used drugs were investigated and punished
      Jiangxi: Several commonly used drugs were investigated and punished
     
      Coincidentally, just a few days ago, the Jiangxi Provincial Food and Drug Administration issued the 2021 Phase 2 Drug Supervision Sampling Information Announcement (hereinafter referred to as the "Announcement").
     
     
      According to the announcement, in order to strengthen drug quality supervision and ensure the safety of drug use by the public, in accordance with the "Drug Administration Law" and related laws pharmnet.
    com.
    cn/" target="_blank">and regulations, and the Jiangxi Province drug sampling plan, the drug regulatory agencies and inspection agencies at all levels in the province are responsible for the production, operation and use of drugs in the province.
    The unit implemented supervision and random inspection.
    Drugs Drugs Drugspharmnet.
    com.
    cn/" target="_blank"> legislationpharmnet.
    com.
    cn/" target="_blank"> and regulations and regulations
     
      After verification, there are 9 batches of 8 varieties that do not meet the requirements, and the items that do not meet the requirements include traits, inspection, content determination, etc.
    After combing, it was found that only 2 of the 8 medicines were Chinese herbal medicine pieces, and the rest were all preparations, involving Fengreganmao granules, Ganmaoling granules, Tongbianling capsules, diclofenac sodium enteric-coated tablets and many other commonly used medicines.
     
      Announcements, Jiangxi Food and Drug Administration has instructed the relevant departments of the test do not meet the prescribed drugs include seizure, detention, suspension of sales, recall and other necessary control measures in accordance with relevant laws and regulations of the production companies and the sampling units in the investigation.
    Enterprise business enterprise
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.